GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
Quick Stats
Jan 30, 202644.3
AI Score
HOLD0.28
Volume Ratio
Feb 20, 2026
Next Earnings
13
+ve Days (30d)
17
-ve Days (30d)
GTBP Stock Summary
Last updated Jan 30, 2026
GTBP is currently trading at $0.6601, positioned below its 200-day moving average of $1.46, suggesting bearish momentum. The stock has a 52-week range of $0.54 to $3.85.
Technical Analysis: The 50-day moving average stands at $0.73, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 42.266, suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is 0.044, which is positive, indicating accumulation by institutional investors. Our AI-powered investment score rates GTBP at 44.3/100 with a HOLD recommendation.
GTBP (GT Biopharma Inc. Common Stock) Indicators
Last updated Jan 30, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 42.266 |
| CMF (20) | 0.044 |
| ROC (10) | -9.575 |
| ADX (14) | 16.954 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | -0.012 |
| AROONOSC (14) | 35.714 |
| WILLAMS %R (14) | -92.225 |
| MFI (14) | 70.47 |
GTBP Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
GTBP Price vs Max Options Open Interest
GTBP Max Change In Options Open Interest
GTBP Options - Sort by Max open Interest (near term)
31st January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
GTBP Daily Out of Money Options - Sort by Max open Interest (near term)
31st January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
GTBP Daily In the Money Options - Sort by Max open Interest (near term)
31st January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
GTBP Most Active Options by Volume(near term)
31st January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
GT Biopharma Inc. Common Stock is not trading above both 50 Day and 200 Day SMA which is considered Bearish.
GTBP Moving Averages Analysis
GTBP (GT Biopharma Inc. Common Stock) Simple Moving Averages
Moving Averages are last updated Jan 30, 2026
| Days | MA |
|---|---|
| 10 | 0.71 |
| 20 | 0.72 |
| 30 | 0.75 |
| 50 | 0.73 |
| 100 | 0.72 |
| 200 | 1.46 |
GTBP Fundamental Analysis
| P/E (Forward) | 0 |
| P/E (Trailing) | -- |
| Market Cap ($) | 18.1 million |
| Earnings/Share ($) | -3.5 |
| Net Proft Margin (%) | 0 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | -1.66 |
| EPS Estimate Next Year ($) | -0.7 |
| WallStreet Target Price ($) | 8 |
| Most Recent Quarter |